
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is anticipated to experience significant sales growth in 2026, with estimates reaching $167 million, representing an increase of approximately 220% year-over-year, well above consensus projections. The company's guidance for Aucatzyl also points towards solid performance, with expected sales between $120-135 million, reflecting about a 70% increase from the previous year. Additionally, with projected capital of around $370 million at the end of 2025, Autolus is well-positioned for expansion, enhancing its commercial prospects and overall valuation as it advances its innovative T-cell therapies.
Bears say
Autolus Therapeutics faced a challenging outlook due to disappointing revenue estimates for FY:26, which are projected at $120-135 million, falling short of previous expectations of $167 million. Additionally, early clinical results from the SLDAI-2K studies indicated limited efficacy in a small patient cohort, raising concerns about the future production of CAR-T therapeutics, which could impact overall revenue generation. These factors have led to a downward revision of estimates for FY:26 and FY:27, highlighting uncertainties surrounding the company's growth and market performance.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares